# Table of Contents

1. **Science & Dissemination**
   - Meetings
     - ESTRO 2022
     - Joint & collaboration events
     - ESTRO workshops
   - Publications
     - The Green Journal
     - Open access journals
   - Research & Dissemination
   - Guidelines

2. **ESTRO School**
   - Teaching courses
   - E-Learning

3. **Membership & Partnerships**
   - Profile of ESTRO members
   - Wide range of membership categories
   - Membership categories under the spotlight
   - RTT Alliance
   - MoUs

4. **ESTRO Cancer Foundation (ECF)**

5. **Financial Report**
   - Treasurer's report for 2022
   - ESTRO audited accounts 2021
   - Cumulative result 2008-2022

6. **Annex**
   - Governance & constituent bodies
   - Staff
   - Corporate members
   - Joint members
   - RTT alliance
   - Institutional members
   - Radiotherapy and Oncology and open access journals
   - Awards
   - Newsletter
Editorial

Three years on from parts of Europe entering their first lockdown, we find ourselves in a very different world and ESTRO, in common with its members, has had to adapt and evolve accordingly. 2022 has been a year of particularly rapid change in many areas but these changes have been underpinned by a renewed sense of community. We have been reminded of the immense value in working together for the good of those we serve but also the enormous joy of face-to-face human collaboration.

Events

I start this report with a reflection on the ESTRO 2022 Congress. The sunlit lowlands of Copenhagen were a glorious backdrop for ESTRO's return to fully-fledged face-to-face conferencing, building on the momentum created by ESTRO 2021. ESTRO 2022 brought together 5,700 stakeholders from across the radiation oncology community. The excitement of colleagues seeing old friends for the first time in years was palpable. Many were also reminded that the opportunity to be away from the day job, deep-diving and discussing the latest research and innovations, is a powerful catalyst for clinical and academic endeavours the rest of the year. For those who couldn't make it in person (and for those that couldn't be in two excellent sessions at once), most of the plenary sessions, symposia and proffered paper sessions were available for leisurely digestion after the event. For the more intimate, and incredibly popular, mini-oral sessions you simply had to be there, and these sessions will be a key component of annual ESTRO congresses going forwards.

Of course, radiation oncology professionals need recharging year-round and this is where ESTRO looks to diversify its offerings going forwards. Workshops, for example, have proved hugely popular and productive. ESTRO organised three highly successful workshops in 2022: the Physics Workshop (Lisbon, 7-8 October 2022) and the GEC-ESTRO Workshop (Nice, 1-2 December 2022) were organised onsite and gathered 156 and 190 participants respectively, whilst the RTT Workshop brought together 65 delegates in a fully online event (15 November 2022 and 16 February 2023). The workshop model as a means of bringing smaller specific interest groups to brainstorm issues of current interest is one that ESTRO seeks to replicate across the society. Focused interactions at the junctures between radiation oncology disciplines have the potential to be particularly fruitful.
Membership
ESTRO membership has increased by around one third over the last decade, 2022 marking an all-time high with nearly 8,300 ESTRO members by the end of the year. Institutional membership continues to represent a large portion of the society’s membership, alongside an increasing number of associations entering into joint membership agreements with ESTRO. Membership proportions are relatively stable with around half of ESTRO members being clinicians, around a quarter medical physicists and around 20% RTTs. ESTRO is keen to grow its radiation biology community as well as providing a home for other radiation-research associated specialities not currently formally represented in our structure.

Education
The ESTRO School built on the achievements of 2021, continuing to deliver a rich and diversified educational portfolio both in content and mode of delivery. While many ESTRO courses were reinstated face-to-face, the School leveraged the opportunities of the online environment to enrich its programmes, be it through recorded lectures, blended courses, or fully online curricula. 2022 confirmed the ESTRO School’s ability to integrate the benefits of the online environment into its educational output. In 2022, 25 courses were organised with a total of 1,879 students, 6 courses having taken place online. In parallel, FALCON contouring workshops continued a steady growth trend, with 432 registered participants for 13 workshops confirming an increasing appetite for being able to access at least some aspects of radiotherapy training online.

Science & dissemination
The ESTRO family of journals continued to grow in 2022 with ctRO obtaining its first Impact Factor in 2021, an impressive 4.739. Site activation for the E²-RADIatE platform saw a steady increase and the OligoCare cohort continued to recruit very well with around 1,680 patients enrolled as of November 2022. ESTRO joined forces with other associations and stakeholders to respond to EU calls for tenders resulting in the EU-REST and MARLIN projects being launched whilst the QuADRANT project concluded in 2022. ESTRO also increased its efforts to streamline guideline initiatives internally, publishing nine internal and joint guidelines and endorsing five guidelines developed by other societies.

Society Affairs
After a brief COVID-19-related hiatus, the ESTRO governance review made a significant leap forward, with Board members and Chairs of all ESTRO governance bodies coming together to resume wider discussions on how to improve accountability, transparency and access within the society. The ESTRO Governance Review White Paper was approved by the Board in September 2022, with the newly formed Professions and Partnerships Council beginning its work the same month. Focus Groups, the new creative think-tanks of our society were approved for launch in 2023 and more detail on these will follow in next year’s report.

Four years on from the publication of the ESTRO Vision 2030, the society also started preparations for a 2023 strategy retreat with the aim of taking stock post-pandemic, reviewing the needs of our community and therefore determining strategic objectives for the next 3-5 years. Top line recommendations will be presented at the 2023 ESTRO General Assembly.
Partnerships

2022 saw renewed Memoranda of Understanding (MoUs) with many national and international partners, including professional associations, site-specific societies and research organisations. The MoUs signed in 2022 were largely multi-area agreements defining ESTRO’s role in joint courses and events, joint membership partnerships, as well as the initiation and endorsement of scientific content. While a large number of stakeholders included European associations, ESTRO also confirmed key partnerships in North America and Australasia. In particular, a new edition of the ESTRO meets Asia congress which will be organised with the Federation of Asian Organizations for Radiation Oncology (FARO) in 2024.

In summary, 2022 has seen ESTRO demonstrate an extraordinary capacity to adapt to the changing needs of the radiation oncology community and the patients it serves. The benefits of working together as one body with one vision, purpose and voice have become even clearer and ESTRO’s new governance structure will underpin focused, inclusive, fruitful and clearly-communicated collaboration between like-minded and energetic individuals. ESTRO has a unique interdisciplinary culture from which we can all benefit. Thanks to the sense of togetherness and spirit shown by our community, we have been able to turn the post-pandemic corner and set the foundations for a stronger and healthier society guided still by ESTRO’s 2030 Vision “Radiation Oncology, Optimal Health For All, Together”. Thank you for being part of this vision.

Anna Kirby
ESTRO President
Mission

The mission of ESTRO, a non-profit, scientific organisation, shall be to foster, in all its aspects, radiotherapy (also known as radiation oncology), clinical oncology and related subjects, including physics as applied to radiotherapy, radiation technology and radiobiology.

To fulfil its mission ESTRO will:

- Develop and promote standards of education in radiotherapy and clinical oncology
- Promote standards of practice in radiotherapy, clinical oncology and related subjects
- Stimulate the exchange of scientific knowledge in all related fields
- Strengthen the clinical speciality of radiotherapy and clinical oncology in relation to other specialities and professions involved in cancer management
- Encourage co-operation with international, regional and national societies and bodies representing radiotherapy, clinical oncology and related subjects
- Facilitate research and development in radiotherapy, clinical oncology and related subjects.
ESTRO has a long track record of organising conferences, disseminating the latest findings and providing a platform for networking hence working towards optimal care for cancer patients.
ESTRO 2022 covered the wide spectrum of radiation oncology through 12 tracks delivering sessions in six different fields, reflecting the highly specialised disciplines of the radiation oncology area:

- Clinical
- Brachytherapy
- Physics
- RTT (Radiation Therapists)
- Radiobiology
- Young.

An interactive hybrid format
Delegates could attend the congress onsite in Copenhagen but they could also join online thanks to a platform that enabled interaction between onsite and online participants. All sessions were live-streamed and recorded to be available on-demand. This allowed all delegates, both onsite and online, to attend a maximum number of sessions.

A top-level scientific programme
Although delegates could join online, all faculty present onsite provided the best audience experience. The latest science in radiation oncology was delivered via symposia, teaching lectures, debates, pitch sessions and panel discussions as well as proffered papers.

Improved presentation formats
New, highly-interactive mini-oral and poster discussion sessions promoted great interaction between presenters and the audience and gave more visibility to submitted work and research.

Young programme
A programme for young delegates was delivered on a dedicated day to provide those in the early stages of their career with the information and tools to make the most of their professional opportunities.

A host of educational activities
In addition to the main scientific programme, several pre-meeting courses and contouring workshops were held. These are discussed in the School section of this report.
PARTICIPATION

5,663 Delegates

- 67% Participants
- 33% Company delegates

90% Onsite participations
10% Online participations

Most Represented Specialities

- 42% Radiation Oncologists
  - Onsite: 80%
  - Online: 20%
- 27% Medical Physicists
  - Onsite: 91%
  - Online: 9%
- 13% RTTs, RT Nurses
  - Onsite: 91%
  - Online: 9%
- 10% Clinical Oncologists
  - Onsite: 79%
  - Online: 21%
- 2% Radiobiologists
  - Onsite: 95%
  - Online: 5%
- 1% Dosimetrist
  - Onsite: 93%
  - Online: 7%
- 1% Computer Scientists
  - Onsite: 93%
  - Online: 7%
- 1% Medical Oncologists
  - Onsite: 97%
  - Online: 3%

67% Participants
90% Onsite participations
33% Company delegates
10% Online participations

5,663 Delegates

67% Participants
33% Company delegates
90% Onsite participations
10% Online participations

Most Represented Specialities

42% Radiation Oncologists
27% Medical Physicists
13% RTTs, RT Nurses
10% Clinical Oncologists
2% Radiobiologists
1% Dosimetrist
1% Computer Scientists
1% Medical Oncologists

- Onsite: 80%
- Online: 20%
- Onsite: 91%
- Online: 9%
- Onsite: 79%
- Online: 21%
- Onsite: 95%
- Online: 5%
- Onsite: 93%
- Online: 7%
- Onsite: 97%
- Online: 3%
### Top 8 countries

<table>
<thead>
<tr>
<th>Country</th>
<th>Participants</th>
<th>Visitors</th>
<th>Onsite</th>
<th>Online</th>
</tr>
</thead>
<tbody>
<tr>
<td>The Netherlands</td>
<td>560</td>
<td></td>
<td>516</td>
<td>44</td>
</tr>
<tr>
<td>UK</td>
<td>466</td>
<td></td>
<td>408</td>
<td>58</td>
</tr>
<tr>
<td>Germany</td>
<td>452</td>
<td></td>
<td>426</td>
<td>26</td>
</tr>
<tr>
<td>Denmark</td>
<td>369</td>
<td></td>
<td>353</td>
<td>16</td>
</tr>
<tr>
<td>France</td>
<td>363</td>
<td></td>
<td>332</td>
<td>31</td>
</tr>
<tr>
<td>USA</td>
<td>338</td>
<td></td>
<td>302</td>
<td>36</td>
</tr>
<tr>
<td>Italy</td>
<td>329</td>
<td></td>
<td>276</td>
<td>33</td>
</tr>
<tr>
<td>Belgium</td>
<td>300</td>
<td></td>
<td>270</td>
<td>30</td>
</tr>
</tbody>
</table>

### ESTRO congress participation evolution

<table>
<thead>
<tr>
<th>Congress</th>
<th>Participants</th>
<th>Visitors</th>
<th>Onsite</th>
<th>Online</th>
</tr>
</thead>
<tbody>
<tr>
<td>ESTRO 35</td>
<td>5,284</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ESTRO 36</td>
<td>5,860</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ESTRO 37</td>
<td>6,211</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ESTRO 38</td>
<td>6,633</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ESTRO 2020</td>
<td>3,047</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ESTRO 2021</td>
<td>4,120</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ESTRO 2022</td>
<td>5,663</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
**EXHIBITION**

110 Exhibitors (online & onsite)

- Exhibitors: 96
- Start-ups: 3
- Community Pavilion: 11 national societies

**Gender**

- 49% Female
- 47% Male
- 4% Not specified

Average 44 years old

**Abstracts**

1,924

**Posters**

1,136

**Chairs**

329

**Sessions**

232

**Invited Speakers**

288

**Sqm**

4,754
2. Joint and collaboration events 2022

2.1 ICHNO-ECHNO 2022

*International Congress on Innovative Approaches in Head and Neck Oncology (ICHNO) joint with the European Congress on Head and Neck Oncology (ECHNO)*

3-5 March 2022 | Brussels, Belgium

The ICHNO-ECHNO congress provided a unique platform for the dissemination of the most relevant and cutting-edge science and innovation in the field of head and neck oncology.

Organised by ESTRO, the European Head and Neck Society (EHNS) and the European Society for Medical Oncology (ESMO), ICHNO-ECHNO has been shaped into a major international event in the promotion of multidisciplinary head and neck oncology.

Due to the Covid-19 restrictions, the congress was offered in a hybrid format, participants could attend it onsite in Brussels or online.
530 Delegates

Top 10 countries

- United Kingdom: 51
- Belgium: 45
- The Netherlands: 40
- France: 38
- Switzerland: 32
- Germany: 28
- Georgia: 24
- Italy: 24
- Other: 20
- USA: 17

Breakdown per speciality

- 48% RO Speciality
  - 22.8% Radiation Oncologist
  - 20.6% Clinical Oncologist
  - 1.5% Medical Physicist
  - 1.5% Other
  - 0.9% Medical Oncologist
  - 0.4% Radiobiologist
  - 0.2% RTT, RT nurse
- 19.2% Other Medical Specialities
- 17.9% Not specified
- 14% RO Industry - Corporate
- 0.9% Other Non-medical Specialities
2.2 European Lung Cancer Conference (ELCC 2022)
30 March - 2 April 2022 | Online

Organised by ESMO (European Society for Medical Oncology) and IASLC (International Association for the Study of Lung Cancer) with ESTRO, European Society of Thoracic Surgeons (ESTS) and the European Thoracic Oncology Platform (ETOP) as partners.

The ELCC is a collaboration of the most important multidisciplinary societies that represent thoracic oncology specialists, working together to advance science, disseminate education and improve the practice of lung-cancer specialists worldwide.

Medical oncologists, radiation oncologists, thoracic surgeons, respiratory physicians/pneumologists, interventional radiologists and pathologists all benefit from its comprehensive programme.

2,236 Participants
99 Countries represented
Average 42 years old

Breakdown of participants
- 89.5% Delegates
- 5.9% Faculty
- 1.8% Industry
- 2.8% Press

Breakdown per speciality
- 81.8% Oncology Clinicians
  (incl. 14.4% Radiation and Medical Oncologists)
- 9.4% Basic scientists
- 4% Pharmacists
- 2.3% Other healthcare professionals
- 2.5% Other
  (nurse, medical student, statistician, patient advocate, science student)

Top 10 countries
- USA: 9.5%
- Spain: 8.9%
- UK: 5.9%
- Switzerland: 5.9%
- Germany: 4.5%
- India: 3.9%
- Czech Republic: 3.6%
- The Netherlands: 3.6%
- Belgium: 3.5%
- Italy: 3.2%

Gender
- 51.4% Female
- 48.6% Male

201 accepted (59.6%)
136 rejected or withdrawn (40.4%)

337 Abstracts
The 14th European Multidisciplinary Congress on Urological Cancers (EMUC22) placed a specific emphasis on the importance of a multi-sectoral approach in the treatment of genitourinary (GU) malignancies.

The EMUC22 scientific programme highlighted the most recent developments in the prevention, diagnosis and best practices in the management of GU cancers.

### Top 10 countries

- The Netherlands: 107
- Portugal: 70
- Spain: 62
- UK: 55
- Italy: 50
- Belgium: 43
- Greece: 43
- Germany: 39
- Romania: 32
- Hungary: 28

### Gender

- 65% Female
- 32% Male
- 3% Not Specified /other

---

2.3 European Multidisciplinary Congress on Urological Cancers (EMUC 2022)

*Working together to improve patient care*

10-13 November 2022 | Budapest, Hungary - Jointly organised by EAU, ESMO and ESTRO
2.4 Endorsed Events

ESTRO endorsed 30 conferences, congresses and courses in 2022.

14th Breast Gynecology Immunology International Cancer Conference (BGIIICC)
20-21 January 2022 | Cairo, Egypt

ATTM 2022
17-19 February 2022 | Assisi, Italy

5th Conference on Small Animal Precision Image Guided Radiotherapy
21-23 March 2022 | Munich, Germany

International Conference on Monte-Carlo Techniques for Medical Applications
11-13 April 2022 | Antwerp, Belgium

Niels Bohr Course on Therapeutic and Diagnostic Medical Physics
2-5 May 2022 | Herlev, Denmark

ISRS 2022
19-23 June 2022 | Milan, Italy

10th Bucharest Oncology School: New Horizons
20-23 June 2022 | Bucharest, Romania and online

11th International Gastrointestinal Liver Urological Cancer Conference (IGILUC)
21-22 July 2022 | Cairo, Egypt

14th Breast Gynecology Immunology International Cancer Conference (BGIIICC)
20-21 January 2022 | Cairo, Egypt

Cervix Cancer BT Teaching Course
1 September 2022 - 1 January 2023 | Online

26th Annual SASRO Meeting
1-3 September 2022 | Baden, Switzerland

Radiomics Toolbox Workflow and Quality Management
7-9 September 2022 | Pavia, Italy

Workshop on Clinical Translation of FLASH Therapy
15 September 2022 | Lausanne, Switzerland

New Modalities in Cancer Imaging and Therapy Workshop
5-8 October 2022 | Erguy, France

2nd International Radiation Oncology Virtual Seminar
6 October 2022 | Online

Arab African International Cancer Congress 2022 (AAICC)
6-7 October 2022 | Cairo, Egypt and online

Modern Radiotherapy Oncology: Multidisciplinary Approaches in the Age of Treatments Guided by Omics Sciences and Artificial Intelligence
7 October 2022 | Olbia, Italy

5th Congress of SEETRO
7-9 October 2022 | Skopje, North Macedonia

3rd Ion Imaging Workshop
13-14 October 2022 | Munich, Germany

New Avenues in the Non-Operative Management of Patients with Rectal Cancer: Time for Discussion
13-15 October 2022 | Montreal, Canada

AI Meets Head & Neck Oncology
14-15 October 2022 | Lausanne, Switzerland

32nd Residential Course on Modern Radiation Oncology: Multidisciplinarity in the Era of Omics and AI Guided Oncology
17-19 October 2022 | Rome, Italy

18th Meet the Professor Advanced International Breast Cancer Course
3-4 November 2022 | Padova, Italy and online

VIII ALATRO Congress
16-18 November 2022 | Lima, Peru

Particle Therapy Teaching Course
17-25 November 2022 | Online

Think Hadrom: Discovering Hadrontherapy within Multidisciplinarity
21 November, 12 December 2022 & 15 February 2023 | Online

XXXII AIRO National Congress
25-27 November 2022 | Bologna, Italy

FLASH Radiotherapy and Particle Therapy (FRPT 2022)
30 November - 2 December 2022 | Barcelona, Spain & online

1st MESTRO Meeting
1-2 December 2022 | Riyadh, Saudi Arabia

Workshop on Patient QA - Use of Advanced Dosimetry Techniques
1-4 December 2022 | Novi Sad, Serbia

Masterclass: Artificial Intelligence, Medical Physics and Radiation Oncology
12-15 December 2022 | Villejuif, France
3. ESTRO Workshops

3.1 2022 Physics Workshop - Science in development
7-8 October 2022 | Lisbon, Portugal

The physics workshops, organised by the ESTRO Physics Committee, are designed to create forums for discussion of topics of interest, the sharing of ideas, the development of joint projects and interaction with industry partners. The workshops were set up in 2017 to enable small numbers of people to come together to focus on specific ‘hot’ topics and how to move them forward.

Five tracks ran in parallel:

- Re-irradiation: improving dose summation for plan
- Joint DREAM (Dose Response, Experiment, Analysis, Modelling): a physics & radiobiology workshop
- Justification and optimisation of KV imaging in IGRT
- Particle Arc Therapy: from concept to clinical reality
- Next generation MR-guided radiotherapy: AI applications for planning and image guidance.

152 Delegates
- 141 Participants
- 11 Company delegates

Top 5 disciplines
- 61% Medical Physicists
- 23% Radiation oncology Industry
- 6% Radiobiologists
- 2% RTTs (Radiation Therapists)
- 1% Dosimetrist
- 7% Other or not specified

Top 5 countries (Participants)

<table>
<thead>
<tr>
<th>Country</th>
<th>Participants</th>
</tr>
</thead>
<tbody>
<tr>
<td>UK</td>
<td>32</td>
</tr>
<tr>
<td>Germany</td>
<td>18</td>
</tr>
<tr>
<td>USA</td>
<td>16</td>
</tr>
<tr>
<td>Belgium</td>
<td>14</td>
</tr>
<tr>
<td>The Netherlands</td>
<td>12</td>
</tr>
<tr>
<td>The Netherlands: 12</td>
<td>12</td>
</tr>
</tbody>
</table>

152 Delegates
3.2 GEC-ESTRO Workshop 2022 - Improving Brachytherapy Together
1-2 December 2022 | Nice, France

The GEC*-ESTRO annual workshop is now a hallmark platform for networking with the seven GEC-ESTRO working groups (Anal-rectal, Brachy-HERO, BRAPHYQS, Breast, Gynae, Paediatric, Head and Neck and Skin, UroGEC).

The 2022 edition covered multiple exciting new aspects of brachytherapy. Each working group presented and analysed a site-specific aspect of modern, image-guided brachytherapy. In addition to the scientific programme, the format of the workshop offered networking opportunities and educational activities with parallel and repeating sessions including industry.

*GEC : The Groupe Européen de Curiethérapie
3.3 2022 RTT Workshop
15 November 2022 & 16 February 2023 | ONLINE

The RTT workshops aim to facilitate scientific collaborations and professional networking within the ESTRO RTT community and to establish recommendations on the future roles of RTT.

The workshop proposed three sessions:

- Evaluation of RTT education - is it fit for the present
- RTT-ADAPT: Enabling the Radiation Therapist (RTT) to embrace future roles through the lens of new technology
- RTT advance practice and how it can change the future of radiotherapy.

64 Delegates

Top 5 disciplines

- 88% RTTs, RT Nurses
- 3% Dosimetrist
- 9% Other

Top 5 countries (Participants)

- UK: 10
- Australia: 8
- Ireland: 7
- The Netherlands: 6
- Canada: 5
1. The Green Journal

Editor-in-chief: Michael Baumann (Heidelberg, Germany)

Radiotherapy and Oncology, known as the Green Journal, is the flagship publication in ESTRO’s family of journals. It covers all aspects of radiation oncology, publishing themed issues, editorials and correspondence, as well as original research and review articles.

Article transfer service to CTRo, Phiro and TipsRo

For manuscripts not selected for publication in Radiotherapy and Oncology, authors may be provided with the option of having their manuscript transferred to an ESTRO Open Access publication.

Submitted papers

- 1,764 submitted manuscripts
  - 366 Accepted
  - 1,323 Rejected
  - 23 Withdrawn or removed

78% REJECTION RATE

- 154 (11.6% of the rejected articles) articles were transferred to CTRo, Phiro or TipsRo and
- 89 (6.7% of the rejected articles) were accepted for publication in the open access journals.

Submitted articles by region

29% Europe
16.5% North and Central America
51.5% Asia
2% Oceania
1% South America

Evolution of the number of articles submitted

2018: 1,528
2019: 1,613
2020: 2,175
2021: 1,755
2022: 1,721
**ACCEPTED PAPERS**

Top 10 countries of accepted papers

- China: 53
- USA: 46
- The Netherlands: 42
- Germany: 35
- Italy: 25
- Denmark: 20
- Canada: 19
- UK: 16
- Belgium: 15
- Switzerland: 15

*The region and country are derived by affiliation of the corresponding author*

**IMPACT FACTOR**

Evolution impact factor

- 2012: 4,520
- 2013: 4,857
- 2014: 4,363
- 2015: 4,817
- 2016: 4,328
- 2017: 4,942
- 2018: 5,252
- 2019: 4,856
- 2020: 6,280
- 2021: 6,901

2022 impact factor not yet known.
MOST CITED ARTICLES IN 2022
Published between 2020 and 2021

107 citations in 2022
Defining oligometastatic disease from a radiation oncology perspective: An ESTRO-ASTRO consensus document
2020

49 citations in 2022
Overview of artificial intelligence-based applications in radiotherapy: Recommendations for implementation and quality assurance
Vandewinckele L., Claessens M., Dinkla A., Brouwer C., Crijns W., Verellen D., van Elmpt W.
2020

47 citations in 2022
Comparing deep learning-based auto-segmentation of organs at risk and clinical target volumes to expert inter-observer variability in radiotherapy planning
Wong J., Fong A., McVicar N., Smith S., Giambattista J., Wells D., Kolbeck C., Giambattista J., Gondara L., Alexander A.
2020

These papers contribute to the 2022 Impact Factor.

MOST DOWNLOADED ARTICLES IN 2022
Regardless of publication date

14,964 downloads in 2022
The tubarial salivary glands: A potential new organ at risk for radiotherapy
2021

9,108 downloads in 2022
Delineation of the neck node levels for head and neck tumors: A 2013 update. DAHANCA, EORTC, HKNPCSG, NCIC CTG, NCRI, RTSG, TROG consensus guidelines
Grégoire, V., Ang, K., Budach, W., Grau, C., Hamoir, M., Langendijk, J., Lee, A., Le, Q., Maingon, P., Nutting, C., O’Sullivan, B., Porceddu, S., Lengele, B.
2014

6,107 downloads in 2022
Radiation-induced neuropathy in cancer survivors
Delanian S., Lefax J.-L., Pradat P.-F.
2012

TOP ARTICLES BY SOCIAL MEDIA ATTENTION *

3,569 social media attention in 2022
The tubarial salivary glands: A potential new organ at risk for radiotherapy
2021

1,410 social media attention 2022
Is low dose radiation therapy a potential treatment for COVID-19 pneumonia?
Kirkby C, Mackenzie M.
2020

293 social media attention 2022
Radiation therapy related cardiia disease risk in childhood cancer survivors: Updated dosimetry analysis from the childhood cancer survivor study
2021

*Social Media Attention is captured as a metric showing cumulative views, shares, likes comments etc. for the past 2 years, regardless of publication date.
2. Open access journals

ESTRO and Elsevier offer three open access journals that foster the dissemination of research in areas of importance to the Society’s membership.

All members of ESTRO are eligible for a discounted fee to publish a paper in any of the three open access journals.

Authors of manuscripts submitted to *Radiotherapy and Oncology* that were not withheld for publication may be offered the opportunity to have their manuscript transferred to *ctRO, phiRO* or *tipsRO*. The decision on whether or not to go ahead with this transfer rests with the author of the article.
2.1 Clinical & Translational Radiation Oncology (ctRO)

Co-editors: Pierre Blanchard (Villejuif, France) and Daniel Zips (Berlin, Germany)

Clinical & Translational Radiation Oncology features research on all aspects of clinical and translational radiation oncology, particularly new developments in experimental radiobiology, clinical interventions and treatments. This includes imaging and biomarker studies with a clinical endpoint, as well as research results from data sciences, epidemiology and oncopolicy.

SUBMITTED PAPERS
Evolution of the number of articles submitted

ACCEPTED PAPERS
Top 5 countries of accepted papers

2021 Impact Factor: 4.739
2022 Impact Factor not known yet.
### MOST CITED ARTICLES IN 2022
Published between 2020 and 2021

<table>
<thead>
<tr>
<th>Citation</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>33 citations in 2021</td>
<td><strong>The tumor microenvironment and radiotherapy response; a central role for cancer-associated fibroblasts</strong></td>
<td>Ansems M., Span P.N.</td>
</tr>
</tbody>
</table>

These papers contribute to the 2022 Impact Factor.

### MOST DOWNLOADED ARTICLES IN 2022
Regardless of publication date

<table>
<thead>
<tr>
<th>Downloads</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>4,802</td>
<td><strong>Dose constraints for whole breast radiation therapy based on the quality assessment of treatment plans in the randomised Danish breast cancer group (DBCG) HYPO trial</strong></td>
<td>Thomsen M.S., Berg M., Zimmermann S., Lutz C.M., Makocki S., Jensen I., Hjelstuen M.H.B., Pensold S., Hasler M.F., Jensen M.-B., Oflersen B.V.</td>
</tr>
<tr>
<td>4,753</td>
<td><strong>Technical design and concept of a 0.35 T MR-Linac</strong></td>
<td>Kluter S.</td>
</tr>
<tr>
<td>2,888</td>
<td><strong>Dose constraints for whole breast radiation therapy based on the quality assessment of treatment plans in the randomised Danish breast cancer group (DBCG) HYPO trial</strong></td>
<td>Thomsen M.S., Berg M., Zimmermann S., Lutz C.M., Makocki S., Jensen I., Hjelstuen M.H.B., Pensold S., Hasler M.F., Jensen M.-B., Oflersen B.V.</td>
</tr>
<tr>
<td>2,723</td>
<td><strong>Technical design and concept of a 0.35 T MR-Linac</strong></td>
<td>Kluter S.</td>
</tr>
</tbody>
</table>

### TOP ARTICLES BY SOCIAL MEDIA ATTENTION *

<table>
<thead>
<tr>
<th>Social Media Attention</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>113</td>
<td><strong>Low dose lung radiotherapy for COVID-19 pneumonia. The rationale for a cost-effective anti-inflammatory treatment</strong></td>
<td>Pedro C Lara, Javier Burgos, David Macias</td>
</tr>
</tbody>
</table>

*Social Media Attention is captured as a metric showing cumulative views, shares, likes comments etc. for the past 2 years, regardless of publication date.
2.2 Physics & Imaging in Radiation Oncology (phiRO)
Co-editors: Ludvig Muren (Aarhus, Denmark) and Daniela Thorwarth (Tübingen, Germany)

Physics & Imaging in Radiation Oncology focuses on medical physics and imaging in radiation oncology. The journal publishes original research articles, reviews, technical notes, short communications and correspondence.

In July 2022 it was announced that phiRO will receive its first Impact Factor in 2023.

SUBMITTED PAPERS
Evolution of the number of articles submitted

2017 2018 2019 2020 2021 2022
72 78 62 133 153 120

ACCEPTED PAPERS
Top 5 countries of accepted papers

The Netherlands: 26
UK: 15
Denmark: 8
Australia: 7
USA: 7

Submitted articles by region

55% Europe
13% North and Central America
24% Asia
6% Oceania
2% Africa

23% REJECTION RATE
MOST CITED ARTICLES IN 2022
Published between 2020 and 2021

36 citations in 2022
Clinical implementation of artificial intelligence-driven cone-beam computed tomography-guided online adaptive radiotherapy in the pelvic region
Sibolt P., Andersson L.M., Calmels L., Sjöström D., Bjelkengren U., Geertsen P., Behrens C.F.
2021

25 citations in 2022
Evaluation of measures for assessing time-saving of automatic organ-at-risk segmentation in radiotherapy
2020

20 citations in 2022
In vivo dosimetry in external beam photon radiotherapy: Requirements and future directions for research, development, and clinical practice
Olaciregui-Ruiz I., Beddar S., Greer P., Jornet N., McCurdy B., Paiva-Fonseca G., Mijnheer B., Verhaegen F.
2020

These papers contribute to the 2022 Impact Factor.

MOST DOWNLOADED ARTICLES IN 2022
Regardless of publication date

2,891 downloads in 2022
Relationship between dosimetric leaf gap and dose calculation errors for high definition multi-leaf collimators in radiotherapy
Kim J., Han J., Hsia A., Li S., Xu Z., Ryu S.
2018

2,876 downloads in 2022
Machine learning applications in radiation oncology
Field M., Hardcastle N., Jameson M., Aherne N., Holloway L.
2021

2,284 downloads in 2022
Clinical implementation of artificial intelligence-driven cone-beam computed tomography-guided online adaptive radiotherapy in the pelvic region
Sibolt P., Andersson L., Calmels L., Sjöström D., Bjelkengren U., Geertsen P., Behrens C.
2021

TOP ARTICLES BY SOCIAL MEDIA ATTENTION *

60 social media attention in 2022
Dose-volume-based evaluation of convolutional neural network-based auto-segmentation of thoracic organs at risk
Noémie Johnston, Jeffrey De Rycke, Yolande Lievens, Marc van Eijkeren, Jan Aelterman, Eva Vandersmissen, Stephan Ponte, Barbara Vanderstraeten
2022

38 social media attention in 2022
Multi-center evaluation of dose conformity in stereotactic body radiotherapy
Lee J., Dean C., Patel R., Webster G., Eaton D.J.
2019

32 social media attention in 2022
A single neural network for cone-beam computed tomography-based radiotherapy of head and neck, lung and breast cancer
Matteo Maspéro, Antonetta C Hoveling, Mark H F Savenije, Tristan C F van Heijst, Joost J C Verhoeff, Alexis N T J Kotte, Cornelis A T van den Berg
2020

*Social Media Attention is captured as a metric showing cumulative views, shares, likes comments etc. for the past 2 years, regardless of publication date.
Technical Innovations & Patient Support in Radiation Oncology (tipsRO)

Editor-in-Chief: Michelle Leech (Dublin, Ireland)

Technical Innovations & Patient Support in Radiation Oncology offers radiation therapists, nurses and allied health professionals a forum for the publication of original research, case reports, practice development and health evaluation articles, reviews, short communications, technical notes and correspondence on topics including treatment planning and workflows, treatment delivery and verification, supportive care, psycho-oncology, education and training.

SUBMITTED PAPERS
Evolution of the number of articles submitted

ACCEPTED PAPERS
Top 5 countries of accepted papers

<table>
<thead>
<tr>
<th>Country</th>
<th>Number of Accepted Papers</th>
</tr>
</thead>
<tbody>
<tr>
<td>Australia</td>
<td>12</td>
</tr>
<tr>
<td>UK</td>
<td>6</td>
</tr>
<tr>
<td>Ireland</td>
<td>5</td>
</tr>
<tr>
<td>USA</td>
<td>5</td>
</tr>
<tr>
<td>The Netherlands</td>
<td>4</td>
</tr>
</tbody>
</table>

29% REJECTION RATE
Most cited articles in 2022
Published between 2020 and 2021

26 citations in 2022
Sarcopenia in cancer: Risking more than muscle loss
Anjanappa M., Corden M., Green A., Roberts D., Hoskin P., McWilliam A., Choudhury A.
☑ 2020

17 citations in 2022
On-line adaptive MR guided radiotherapy for locally advanced pancreatic cancer: Clinical and dosimetric considerations
Placidi L., Romano A., Chiloiro G., Cusumano D., Boldrini L., Cellini F., Mattucci G.C., Valentini V.
☑ 2020

10 citations in 2022
Personalised treatment for older adults with cancer: The role of frailty assessment
O’Donovan A., Leech M.
☑ 2020

These papers contribute to the 2021 Impact Factor.

MOST DOWNLOADED ARTICLES IN 2022
Regardless of publication date

5,602 downloads in 2022
Side effects in breast implants related to radiotherapy in breast cancer reconstructive surgery
Winkel de Faria Castro Fleury, E., Jasmin Huanca Bernal, K., Lucena Miranda Madeiro, A., Luis Cervera Ocana, W., Carlos Vendramini Fleury, J., Caobianco, L.
☑ 2021

3,138 downloads in 2022
Surface guided radiation therapy: An international survey on current clinical practice
Batista V., Gober M., Moura F., Webster A., Oellers M., Ramthol M., Kugele M. et al
☑ 2022

1,571 downloads in 2022
Sarcopenia in cancer: Risking more than muscle loss
Anjanappa M., Corden M., Green A., Roberts D., Hoskin P., McWilliam A., Choudhury A.
☑ 2020

TOP ARTICLES BY SOCIAL MEDIA ATTENTION *

347 social media attention in 2022
Analysis of dose using CBCT and synthetic CT during head and neck radiotherapy: A single centre feasibility study
☑ 2020

99 social media attention in 2022
Advanced practice: An ESTRO RTTC position paper
Duffton A., Devlin L., Tsang Y., Mast M., Leech M.
☑ 2019

74 social media attention in 2022
Side effects in breast implants related to radiotherapy in breast cancer reconstructive surgery
Winkel de Faria Castro Fleury, E., Jasmin Huanca Bernal, K., Lucena Miranda Madeiro, A., Luis Cervera Ocana, W., Carlos Vendramini Fleury, J., Caobianco, L.
☑ 2021

*Social Media Attention is captured as a metric showing cumulative views, shares, likes comments etc. for the past 2 years, regardless of publication date.
2.4 ESTRO Newsletter

The ESTRO Newsletter is published online on the ESTRO website. It provides a more informal space for members to read about the latest developments in radiation oncology and its community.

In each issue expert editors, selected from the membership, curate contents for themed disciplinary ‘Corners’ or report on specific topics. The newsletter typically includes information on the latest advances in research and practice, interviews with key opinion leaders, conference findings, a selection of research papers and paper reviews.

Find all articles on the ESTRO Website: www.estro.org/About/Newsroom/Newsletter

Top five most read corners in 2022

1. Read it before your patients
2. Conferences
3. Young ESTRO
4. Brachytherapy
5. RTT

Top 5 most read articles in 2022

1. CONFERENCES CORNER
First Middle East Radiation Oncology Society (MESTRO) Conference 2022
Saad Alrashidi, Saudi Arabia

2. READ IT BEFORE YOUR PATIENTS
Neoadjuvant Chemoradiotherapy Versus Upfront Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Long-Term Results of the Dutch Randomised PREOPANC Trial
Eva Versteijne, Jacob L van Dam, Mustafa Suker, Quisette P Janssen, Janine M Akkermans-Vogelaar, Marc G Besselink, Bert A Bonsing, Jeroen Buijsen, Olivier R Busch, Geert-Jan M Creemers, Ronald M van Dam, Ferry A L M Eskens et al, Dutch Pancreatic Cancer Group
J Clin Oncol. 2022 Jan 27

3. SOCIETY LIFE CORNER
ESTRO 2022 presidential and board elections – a word from the president
Ben Slotman

4. RTT CORNER
IGRT and its practice parameters
Debojoyti Dhar, India

5. YOUNG CORNER
Climate change, ESTRO and radiotherapy
Robert Chuter, UK
E²-RADIATE
EORTC-ESTRO Radiation infrastructure for Europe

E²-RADIatE (EORTC 1811 study) is a platform that collects real-world data through prospective data registries in radiotherapy. Based on a collaboration between the European Organisation for Research and Treatment of Cancer (EORTC) and ESTRO, the project aims to be a pan-European infrastructure and a more efficient framework across the field of radiation oncology to generate robust data in cancer treatment and to further develop and integrate the discipline into therapeutic strategies.

E²-RADIatE comprises three innovative cohorts:
- OligoCare (EORTC 1822-RP)
- ReCare (EORTC 2011-RP).

OligoCare (EORTC 1822-RP)
OligoCare is a pragmatic observational cohort study to evaluate radical radiotherapy for patients with oligometastatic disease. The main objective is to identify patient, tumour, diagnostic and treatment characteristics impacting overall survival, when all cancer sites are treated with definitive local therapy.

OligoCare continues to recruit very well with 1,680 patients enrolled (cut-off 7 November 2022) in 44 institutions across Austria, Belgium, Czech Republic, France, Germany, Switzerland, Italy, The Netherlands, Spain, Slovenia and United Kingdom.

The next pages explain the research activities with which ESTRO was involved in 2022.
The European Particle Therapy Network (EPTN) is an ESTRO task force that was launched in 2017 as the number of clinical proton-therapy facilities in Europe was increasing rapidly, from five in 2009 to more than 30 in 2020. Most of these centres are hospital-based, and many are academic.

The eighth annual workshop was the first in-person meeting since the pandemic and so enjoyed wide representation, 35 participants came from 18 institutions in 11 European countries. The eighth EPTN workshop took place on 5 October 2022 at Particle Therapy Interuniversity Centre, Leuven, Belgium.

You can read about progress across the seven work packages, updates from European Union projects and other initiatives of interest to the network via this link: [www.estro.org/Science/Activities/EPTN](http://www.estro.org/Science/Activities/EPTN)

ESTRO joined forces with other associations and stakeholders to respond to the European Commission tender addressing Call HADEA/2022/OP/000: Service contract for analysis on workforce availability, education and training needs for the quality and safety of medical applications involving ionising radiation in the EU.

The resulting EU-REST project (European Union Radiation, Education, Staffing & Training) started on 1 September 2022 and will last until 31 August 2024. The project aims to provide an analysis of workforce availability, education, and training needs to ensure quality and safety aspects of medical applications involving ionising radiation in the EU, and foresees the development of staffing and education/training guidelines for key professional groups involved in ensuring radiation safety and quality of medical radiation applications in the EU member states.
ESTRO joined forces with other associations and stakeholders to respond to the EU call for tender ENER/D3/2022-402 (ENER/LUX/2022/OP/0008): SAMIRA study on reporting and learning from patient-related incidents and near misses in radiotherapy, interventional cardiology, nuclear medicine and interventional and diagnostic radiology.

The resulting MARLIN project (Medical Applications of Radiation – Learning from Incidents and Near Misses) will run for 24 months and will support the implementation of Council Directive 2013/59/Euratom, specifically articles 63c-e and 104.5, by providing a comprehensive description of the current status of incident reporting.

It is important that the use of ionising radiation in the diagnosis and treatment of diseases is carefully monitored and measures are taken to minimise both the frequency and harm caused by accidental or unintended exposures to patients, according to the relevant articles of the Basic Safety Standards Directive (BSSD). The use of incident learning systems (ILSs), anonymous notification systems where incidents and near misses can be investigated and possible flaws in a process can be identified and rectified, will be studied with regard to their compliance with the BSSD and other regulatory requirements and their role in improving patient safety.

The QuADRANT project “Constant improvement in quality and safety of radiology, radiotherapy and nuclear medicine through clinical audit” (project accepted under call for tenders N° ENER/D3/2019-231-2) started in January 2020 and concluded in December 2022. The QuADRANT project was led by the European Society of Radiology (ESR) together with the European Association of Nuclear Medicine (EANM) and ESTRO as consortium partners.

QuADRANT aims to promote constant improvement in quality and safety of radiology, radiotherapy and nuclear medicine through the implementation of clinical audit as part of Member States’ healthcare systems.

A paper highlighting the project - purpose, structure, findings - is submitted for publication in Insights into Imaging, a journal of ESR, insightsimaging.springeropen.com. This will be accompanied by an editorial in Radiotherapy and Oncology, the ESTRO journal.
GUIDELINES

The ESTRO Guidelines Committee coordinates the development and prioritisation of all ESTRO clinical and technical guidelines in the field of radiation oncology. It also contributes to multidisciplinary guidelines involving other professional oncology and medical physics societies both within Europe and internationally.

The following guidelines were developed under the auspices of the ESTRO Guidelines Committee in 2022 (click to access):

- GEC-ESTRO ACROP prostate brachytherapy guidelines
- European Society for Radiotherapy and Oncology Advisory Committee in Radiation Oncology Practice consensus recommendations on patient selection and dose and fractionation for external beam radiotherapy in early breast cancer
- Perspective paper about the joint EANM/SNMMI/ESTRO practice recommendations for the use of 2-[18F]FDG-PET/CT external beam radiation treatment planning in lung cancer
- ESTRO-ACROP guideline on surface guided radiation therapy
- ESTRO ACROP and SIOPE recommendations for myeloablative total body irradiation in children
- ESTRO ACROP guidelines for external beam radiotherapy of patients with complicated bone metastases
- ESTRO ACROP guidelines for external beam radiotherapy of patients with uncomplicated bone metastases
- GEC-ESTRO ACROP Recommendations on Calibration and Traceability of HE HDR-PDR Photon-Emitting Brachytherapy Sources at the Hospital Level
- Recommendations for Radiation Therapy in Oligometastatic Prostate Cancer: an ESTRO-ACROP Delphi consensus.

The following guidelines were endorsed by the ESTRO Guidelines Committee in 2022 (click to access):

- Joint EANM/SNMMI/ESTRO practice recommendations for the use of 2-[18F]FDG PET/CT external beam radiation treatment planning in lung cancer V1.0
- 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS): Developed by the task force on cardio-oncology of the European Society of Cardiology (ESC)
- Radiation Therapy for Brain Metastases: An ASTRO Clinical Practice Guideline
- Radiation Therapy for IDH-Mutant Grade 2 and Grade 3 Diffuse Glioma: An ASTRO Clinical Practice Guideline
ESTRO SCHOOL
The ESTRO School's mission is to:

- improve, professionalise and harmonise knowledge and practice in radiation oncology and associated professions in Europe and beyond.

To this end, the School:

- offers a wide range of live educational activities and online educational resources that enable professionals worldwide to acquire the most recent knowledge, skills and competencies in their daily practice.

- supports the implementation of the European Core Curricula with education and training programmes that target both young and senior radiation oncology professionals to deliver high-quality treatment and care to cancer patients.

In 2022, the ESTRO School demonstrated adaptability in a context still marked by travel and gathering restrictions due to Covid-19, and pursued its efforts to allow the community to keep track with education and knowledge.

In 2022, half of the teaching courses were held online. Several new formats have been developed to enrich the educational programme and make it accessible to everyone:

- Pre-recorded lectures
- Live online lectures
- Modules spreading the programme over several weeks, or condensed in a few days
- Live broadcasting of some courses with the faculty members teaching live at the ESTRO office (using the ONLINE PLUS format)
1. TEACHING COURSES

1.1 A RICH PALETTE ON OFFER

The portfolio of live teaching courses includes basic and more advanced courses that are targeted at the various radiation oncology professions.

The topics cover the main areas of radiation oncology and multidisciplinary cancer treatment courses on:

- Radiotherapy treatment planning and delivery: external beam and brachytherapy
- Multimodal cancer treatment, in general and also site-specific treatment
- Imaging
- Best practice
- Research
- Biological aspects of radiation oncology.

1.2 2022 AT A GLANCE

Top 5 most attended courses

- 145 participants
  Basic Clinical Radiobiology
- 124 participants
  Implementation and Practice of Image-guided Stereotactic Body Radiotherapy
- 107 participants
  Physics for Modern Radiotherapy
  (a Joint Course for Clinicians and Physicists)
- 105 participants
  Particle Therapy
- 91 participants
  Image-Guided and Adaptive Radiotherapy

<table>
<thead>
<tr>
<th>Participants</th>
<th>Online courses</th>
<th>Onsite courses</th>
</tr>
</thead>
<tbody>
<tr>
<td>1,879</td>
<td>6</td>
<td>19</td>
</tr>
<tr>
<td>1,210 Members</td>
<td>669 Non-Members</td>
<td>19 Participants</td>
</tr>
</tbody>
</table>
Breakdown participants per continent - Courses online and onsite

- Australia: 190
- Romania: 170
- United Kingdom: 138
- The Netherlands: 138
- Belgium: 84
- Norway: 80
- Switzerland: 80
- Germany: 80
- Denmark: 72
- Slovenia: 69

Top 10 countries - Courses online and onsite

- Australia: 190
- Romania: 170
- United Kingdom: 138
- The Netherlands: 138
- Belgium: 84
- Norway: 80
- Switzerland: 80
- Germany: 80
- Denmark: 72
- Slovenia: 69

Growth in the number of courses and participants over the years

- Courses: 1,434, 1,626, 1,717, 1,912, 2,117, 2,412, 2,716, 3,018
- Participants: 1,879, 968, 853, 756, 659, 584, 509, 434
1.3 PRE MEETING COURSES

The first day of the annual congress is always dedicated to teaching courses. Five pre-meeting courses took place onsite in Copenhagen on 6 May 2022 at the occasion of ESTRO 2022.

Number of participants per pre-meeting course

<table>
<thead>
<tr>
<th>Subject</th>
<th>Title</th>
<th>Participants</th>
</tr>
</thead>
<tbody>
<tr>
<td>PHYSICS</td>
<td>Real-world implementation of adaptive radiotherapy in clinical practice</td>
<td>112</td>
</tr>
<tr>
<td>RTT</td>
<td>Time to adapt: Future roles of RTT</td>
<td>63</td>
</tr>
<tr>
<td>CLINICAL</td>
<td>Integration of radiotherapy into targeted or immunotherapy</td>
<td>61</td>
</tr>
<tr>
<td>BRACHY THERAPY</td>
<td>Multidisciplinary approach to high-risk skin cancer with special focus on brachytherapy</td>
<td>46</td>
</tr>
<tr>
<td>RADIO BIOLOGY</td>
<td>Innovative models to assess efficacy and toxicity treatment combination with radiotherapy</td>
<td>36</td>
</tr>
</tbody>
</table>
## 2. E-LEARNING

### 2.1 Training in delineation

An accurate and precise anatomical contouring of target volume and OaRs* is of utmost importance in radiotherapy. FALCON**, ESTRO’s contouring programme, allows radiation oncology professionals to improve their contouring skills.

In using the FALCON EduCase software, trainees can compare their individual contours with those made by delineation experts and visualise the ESTRO international guidelines.

---

* Organs at Risk  
** Fellowship in Anatomic deLineation and CONtourings

FALCON is integrated into the whole portfolio of the educational ESTRO activities:

<table>
<thead>
<tr>
<th>Live courses</th>
<th>Workshops at ESTRO meetings</th>
<th>Online virtual workshops</th>
<th>Support services for clinical trials and development of guidelines</th>
<th>Delineation workshops for other societies (IAEA, national societies or other societies active in the field of oncology)</th>
</tr>
</thead>
</table>
2.2 Online delineation workshops

Top 3 countries

- Australia: 119
- UK: 48
- Romania: 38

Geographic distribution of participants at online blended FALCON workshops

- 58% Europe
- 28.5% Oceania
- 7.2% Asia
- 2.8% Middle East
- 2% North America
- 1% South America
- 0.5% Africa

Evolution of number of participants at online delineation workshops

<table>
<thead>
<tr>
<th>Year</th>
<th>Participants</th>
</tr>
</thead>
<tbody>
<tr>
<td>2015</td>
<td>106</td>
</tr>
<tr>
<td>2016</td>
<td>70</td>
</tr>
<tr>
<td>2017</td>
<td>8</td>
</tr>
<tr>
<td>2018</td>
<td>274</td>
</tr>
<tr>
<td>2019</td>
<td>285</td>
</tr>
<tr>
<td>2020</td>
<td>13</td>
</tr>
<tr>
<td>2021</td>
<td>14</td>
</tr>
<tr>
<td>2022</td>
<td>471</td>
</tr>
</tbody>
</table>

Participants vs Workshops
2.3 Delineation workshops at the ESTRO annual congress

In addition to the pre-meeting courses, ESTRO offers hands-on delineation workshops in the framework of the annual congress.

Number of participants per contouring workshop:

- SCLC (Small Cell Lung Cancer): 21 participants
- Lung Reirradiation: 22 participants
- Prostate SBRT: 50 participants
- Special RTT (Radiation Therapist) Workshop: 12 participants
- Liver Lymph Node SBRT: 9 participants

114 Participants

5 Contouring workshops held onsite at ESTRO 2022
With more than 8,000 radiation oncology professionals from across the world, the ESTRO membership is the heart of our society. ESTRO contributes to the day-to-day practice and career advancement of oncology professionals through the dissemination of the latest trends in practice, research findings and knowledge.
ESTRO offers several levels of membership, with benefits tailored to the needs of each member and their degree of involvement within the society.

The full range of ESTRO membership benefits includes:

- Belonging to a community of more than 8,000 radiation oncology professionals
- Reduced fees for attending ESTRO congresses, workshops and courses
- Networking opportunities
- Online access to scientific material, including event webcasts and delineation cases
- Subscription to *Radiotherapy and Oncology*, the society’s journal, and reduced members’ fees for publishing in the ESTRO open access journals
- Eligibility for mentorship programme, grants, awards, ESTRO faculties and governance positions
- Voting rights at the ESTRO General Assembly
1. Profile of ESTRO Members

The ESTRO community extends far beyond these professional radiation oncology disciplines, taking in a wide range of other professions. This includes professionals from:
- other medical fields, such as surgeons, radiologists, medical oncologists, gynaecologists and urologists
- and non-medical fields, such as public affairs specialists.

Breakdown of ESTRO members by speciality:
- 43.5% Radiation oncologists
- 19.7% Medical physicists
- 12.4% RTTs - nurses - dosimetrists
- 7.6% Clinical oncologists
- 1.1% Radiobiologists
- 15.7% Other medical and non-medical specialities

Top 10 countries:
- The Netherlands: 10.5%
- Switzerland: 6.7%
- United Kingdom: 6.6%
- Italy: 6.2%
- Germany: 5.8%
- Belgium: 5.7%
- Australia: 5.6%
- Denmark: 4.4%
- Canada: 3.8%
- Spain: 3.5%

Geographical distribution:
- 72.1% Europe
- 8.2% Asia
- 8.2% Americas
- 6.7% Oceania
- 0.8% Africa
- 4.0% Unknown
After two years of pandemic, the ESTRO membership increased again in 2022 to reach a record with more than 8,000 members.
2. A wide range of membership categories

- **54.5%**
  INDIVIDUAL MEMBERS
  (4,526)
  - 31.2% FULL (2,590)
  - 30.2% Active (2,504)
  - 0.9% Supporting Ambassador (76)
  - 0.1% Emeritus (10)
  - 23.3% ASSOCIATE (1,936)
  - 16.9% Affiliate (1,400)
  - 6.4% In-Training (527)
  - 0.1% Honorary (9)

- **21.6%**
  INSTITUTIONAL MEMBERS
  (1,795)
  - 51 Institutes

- **15.4%**
  JOINT MEMBERS
  (1,246)
  - 9% Joint (746)
  - 6.4% Joint In-Training (527)

- **6%**
  RTT ALLIANCE MEMBERS
  (494)
  - 24 National societies

- **2.5%**
  CORPORATE MEMBERS
  (206)
  - 33 Companies
3. Membership categories under the spotlight

1. Institutional membership

The institutional membership is designed for centres aiming to support their oncology teams in their professional development. It also fosters interdisciplinarity and multidisciplinarity within the departments.

With this category, centres can purchase individual memberships on behalf of their employees, with very attractive conditions.

Centres also benefit from an increased visibility with:

- A dedicated institutional webpage on the ESTRO website
- A complimentary networking space in the Communities Pavilion during the annual congress
- Free online job postings
- An “ESTRO institutional member” logo.

New institutional members in 2022:

- Basel, St. Claraspital
- Basel, Universitäts Spital Basel (USB)
- Bellinzona, Ospedale San Giovanni (EOC)
- Bern, Inselspital (Universitäts Spital Bern)
- Fribourg, Hôpital Cantonal (HFR)
- Genève, Hôpitaux Universitaires (HUG)
- Genolier, Clinique de Genolier
- La Chaux-de-Fonds, Réseau Hospitalier Neuchâtelois (RHNe)
- Lausanne, Clinique La Source
- Lausanne, Hirslanden Clinique de Bois-Cerf
- Lugano, Gruppo Ospedaliero Moncucco
- Paul Scherrer Institut (PSI)
- Radio-Onkologie-Zentrum KSA-KSB
- Sion, Hopital du Valais
- Winterthur, Kantonsspital Winterthur (KSW)
- Zürich, Stadtspital Triemli.

List available in the Annex

New institutional members in 2022:

- Basel, St. Claraspital
- Basel, Universitäts Spital Basel (USB)
- Bellinzona, Ospedale San Giovanni (EOC)
- Bern, Inselspital (Universitäts Spital Bern)
- Fribourg, Hôpital Cantonal (HFR)
- Genève, Hôpitaux Universitaires (HUG)
- Genolier, Clinique de Genolier
- La Chaux-de-Fonds, Réseau Hospitalier Neuchâtelois (RHNe)
- Lausanne, Clinique La Source
- Lugano, Gruppo Ospedaliero Moncucco
- Paul Scherrer Institut (PSI)
- Radio-Onkologie-Zentrum KSA-KSB
- Sion, Hopital du Valais
- Winterthur, Kantonsspital Winterthur (KSW)
- Zürich, Stadtspital Triemli.

List available in the Annex

2. Supporting ambassador membership

This membership category is reserved for professionals in the field of radiation oncology who are strongly committed to supporting the ESTRO activities in the enhancement of the radiotherapy community.
3. In-Training members and members up to 40 years old

It is essential for ESTRO to invest and connect with the next generation of healthcare professionals and decision-makers.

To this end, ESTRO consolidates its collaboration with European societies representing the new generation of radiation oncology professionals and encourages them to join the society.

ESTRO In-Training members are professionals in the field of radiation oncology who are in training or full time PhD and have obtained their diploma within the last 10 years.

Illustrations of the involvement of the new generation of professionals in the ESTRO community

The Young Corner
Dedicated section in the ESTRO newsletter with news from young national societies and young members sharing their experience through meetings, travel grant reports, etc.

The Young Track
Full-day programme held during ESTRO’s annual congress, which focuses specifically on topics of interest to young professionals.

Opinion Panel
Online, bi-monthly questionnaire where panelists share their opinion on the yESTRO Committee activities and take their first step within the ESTRO community.

3,810 Young ESTRO members (In training and members up to 40 years old) in the society in 2022

Breakdown of In-Training members

Evolution of In-Training members

<table>
<thead>
<tr>
<th>Year</th>
<th>Individual In-Training</th>
<th>Joint In-Training</th>
<th>Institutional In-Training</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>2017</td>
<td>877</td>
<td></td>
<td></td>
<td>877</td>
</tr>
<tr>
<td>2018</td>
<td>862</td>
<td></td>
<td></td>
<td>862</td>
</tr>
<tr>
<td>2019</td>
<td>1,012</td>
<td></td>
<td></td>
<td>1,012</td>
</tr>
<tr>
<td>2020</td>
<td>1,208</td>
<td></td>
<td></td>
<td>1,208</td>
</tr>
<tr>
<td>2021</td>
<td>1,194</td>
<td></td>
<td></td>
<td>1,194</td>
</tr>
<tr>
<td>2022</td>
<td>1,358</td>
<td></td>
<td></td>
<td>1,358</td>
</tr>
</tbody>
</table>
4. Joint membership

This category can be granted to individual members who benefit from a joint membership agreement, signed on a case-by-case basis between ESTRO and a non-European society or a young national society active in the field of radiation oncology. In 2022, ESTRO counted 1,276 joint members.

5. Corporate members

With the ESTRO Corporate membership, the industry has privileged access to the global radiotherapy and oncology community. Gold Corporate members are invited to engage with ESTRO and its community via the ESTRO Advisory Corporate Council. As council members, they have the opportunity to give their views on the clinical practice in radiation oncology and support the long-term objectives of the society.

Corporate members in 2022

33 corporate members:
- 13 gold members
- 20 regular members
RTT Alliance

The objective of the RTT Alliance, initiated by ESTRO a few years ago, is to strengthen the collaboration with national societies representing RTTs, at both European and international level.

In 2022, one additional national societies joined the RTT Alliance:
- Radiotherapists’ Association of Tanzania (RAOTA).

24 National societies members of the RTT Alliance

MoUs

Memoranda of understanding (MoUs) on science, education and membership are key agreements that enable ESTRO to establish new collaborations and nurture existing ones with other societies in the field of oncology.

In 2022, ESTRO signed MoUs with the following national and international societies:
- Spanish Society of Medical Physics (SEFM in training)
- International Atomic Energy Agency (IAEA)
- European Association for Dermato-Oncology (EADO)
- Paediatric Radiation Oncology Society (PROS)
- Royal Australian and New Zealand College of Radiologists (RANZCR).

Additional MoUs are being drafted and renewed in 2023.

Full list available in the Annex.
The ESTRO Cancer Foundation (ECF) continues its efforts to foster the outreach of radiotherapy at the European level, especially by implementing the Value Based HealthCare (VBHC) project and UpLung, a project initiated in 2020. Both initiatives aim to improve the access of patients to high-quality radiotherapy treatment.

Two projects are currently ongoing under the auspices of the ECF.
The Value Based Health Care (VBHC) project is an ESTRO/ECF - HERO Project. The landscape of innovative interventions in radiotherapy is diverse and complex in terms of technologies, techniques and treatment schemes.

The project will aim to provide a better view and agreement on different types and categorisation of innovative interventions in radiation oncology. This is the first necessary step to support policy-making and reimbursement schemes, allowing for optimisation of patient access to radiotherapy.

Supported by a grant from Elekta and Varian, the project will run for three years.

Utilisation of radiotheraPy for Lung cancer in Europe (UpLung) is an ESTRO/ECF-HERO project. This research initiative was launched in November 2020 aiming to explore the challenges to the uptake of radiotherapy for lung cancer patients in Europe.

Supported by a grant from AstraZeneca, this project will use qualitative and quantitative research to characterise the radiotherapy access landscape in Europe and develop policy recommendations to improve patient outcomes by closing gaps in access to high-quality radiotherapy.
5 FINANCIAL REPORT
1. Treasurer’s report for 2021

Dear Friends,

In last year’s report, being carefully optimistic, I quoted Nietzsche ("was mich nicht umbringt, macht mich stärker"). This year, we can claim with a reasonable degree of confidence that indeed we managed the turbulent years with minimal damage. The combined efforts of you as members and the ESTRO office, showing with large amount of flexibility and adaptation, safeguarded our financial stability. We are not out of the woods yet, but we can start making plans for the future again. And indeed, the new governance structure and the outcome of the recent strategy retreat show promise with new building blocks for a strong, solid and future-proof Society.

If we look at 2021 in detail: the auditors provide an unqualified opinion and showed a total net result of €44k including financial and extraordinary charges. While the total revenue generated by the ESTRO activities mounted to €6.02M, the total of expenditures represented an amount of €5.94M. In short, a clear break-even.

Concerning 2022, as usual, the accounts are being audited at the time of writing and the final result will be presented for approval at the General Assembly on 15 May 2023. As mentioned earlier we managed to face the challenges of the last years, yet we still need to monitor the operational costs carefully. This approach paid off: as the intermediate forecast (presented in May 2022) indicated that we would not meet the approved budget, we can now anticipate a final result that matches the original budget. Revenues and expenses at the end of 2022 are estimated at €8.08M and €7.55M respectively, with an expected net result of €450k (including the financial and extraordinary results).

The ESTRO Portfolio (a defensive, Social Responsible (ethical) Investment profile, managing the cash reserves) was of course impacted by the pandemic and the war in Ukraine (with a negative return in 2022, which seems to have recovered at the start 2023). The total reserve shows a capital of €2.03M at the end of January 2023, which is not too bad considering the general economic situation.

To close this report, I would like to thank you all for your commitment to ESTRO and our industry partners for the continuous support. All things considered, together we seem to be managing this crisis quite well. As always, please feel free to contact me anytime with questions or concerns regarding ESTRO’s financial situation, and of course, I look forward to meeting you all, in person, at our annual meeting in Vienna.

Warm regards, and as always, think pink,

Dirk Verellen
ESTRO Treasurer

*What does not kill me, makes me stronger*
The figures presented in this report were approved at the ESTRO general assembly on 9 May 2022.

In 2021, operating revenues rose to almost €6,018 million, led by registrations at meetings and courses and exhibition subscriptions.

The financial incomes represented an amount of €3,000 while the financial charges, including bank charges and credit card commissions, represented €41,000.

With operating expenses of €5,936 million the net impact of income and expenditure is a net result of €44,000.

Net Result (Net Profit) €44,000
3. Cumulated result 2008 - 2022
ANNEX 6
1. Governance & Constituent Bodies
National societies Committee

Barbara Alicja Jereczek-Fossa - Milan, Italy Chair
Nuria Jornet - Barcelona, Spain Education Council & Physics Committee Representative
Esther Troost - Dresden, Germany Clinical Committee Representative (before the General Assembly)
Christina Garbini - Milan, Italy Physics Committee Representative
Li Tie Tan - Cambridge, UK GE ESTRO Committee Representative
Barbara Bal - Poznan, Poland RTT Committee Representative (before the General Assembly)
Ludwig van den Bergh - Ghent, Belgium RTT Committee Representative
Masa Dzhugashvili - Murcia, Spain Board-nominated Representative
Daan Nevens – Antwerp, Belgium Young Committee Representative

Updates after the General Assembly

Dorota Gabrys - Gliwice, Poland Clinical Committee Representative
Pedro Lara - Las Palmas de Gran Canaria, Spain Clinical Committee Representative
Christian Richter - Dresden, Germany Physics Committee Representative
Banu Atalar - Istanbul, Turkey Full member

Radiation Oncology Safety and Quality (ROSSQ) Committee

Mary Coffey - Dublin, Ireland Chair
Amanda Caissie - Halifax, Canada
Antonia D’Ottaviano - Dubin, Ireland
Brian Louwens - Toronto, Canada
Dirk Vellien - Antwerp, Belgium
Geoff Delaney - Sydney, Australia
Mavee Keaney - Dubin, Ireland
Michael Mussevici - Toronto, Canada
Pietro Bejlkjers-Thijsse - Maastricht, The Netherlands
Philippe Malgrange - Paris, France
Velimir Markovski - Zagreb, Croatia
Sophie Perryc - Zurich, Switzerland Young Committee Observer

Task Force: European Particle Therapy Network (EPTIN)

Organisers:
Cai Grau - Aarhus, Denmark
Damen Weber - Villigen, Switzerland
Dieter Geigl - Vienna, Austria

Work Packages (WP)

WP1 - Clinical coordinators
Hans Langendijk - Groningen, The Netherlands Leader
Daniel Zips - Tuebingen, Germany
Esther Troost - Dresden, Germany
Jacques Buisson - Grenoble, France
Karin Haustermann - Leuven, Belgium
Roberto Orecchia - Milano, Italy
Oliver Jäckel - Heidelberg, Germany
Omar Jaffar - Villigen, Switzerland
Stefano Lorentini - Trento, Italy
Aswin Hoffmann - Dresden, Germany
Alessandra Bolsi - Villigen, Switzerland

WP2 Dose assessment, quality assurance, dummy runs, technology inventory

WP3 Education
Monten Hoyer - Aarhus, Denmark
Marco Schwarz - Trento, Italy

WP4 Image guidance in particle therapy

WP5 TPS in particle therapy

WP6 Radiobiology, RBE

WP7 Health economy

HERO Group

Ajoy Agrawal - London, UK Chair
Yolande Laveau - Ghent, Belgium Co-chair
Cai Grau, Aarhus, Denmark
Josep Borras - Barcelona, Spain
Judith van Loon - Maastricht, The Netherlands
Julietta Corral - Barcelona, Spain
Noémie Defourny - Manchester, UK

Full member

Noémie Defourny - Manchester, UK

Full members

Klaus Nagels - Bayreuth, Germany

Full members
2. Staff

**CEO**
Alessandro Cortese

**Society affairs & executive office**
Chiara Gasparotto
Deputy CEO

Evelyn Cherwenske
Manager Society Affairs & Research Projects

Simone De Ioanna
Governance & Education Project Manager

Clarine Musso
Society Affairs Coordinator

**Education**
Laura La Porta
Senior Manager Education

Agne Delmas
Committees & Education Project Manager

Karolina Kowska
Committees & Education Project Manager

Andrea Colaresi
Governance & Education Project Manager

Mika Palu
Senior Project Manager

**Science**
Erda Asztalos
Senior Manager Science

Jessica Pledge
Scientific Programme Manager

Jonas Johansen
Coordinator Scientific & R&D projects

**Membership & partnerships**
Valerie Crommelynck
Membership & Partnerships Manager

**Marketing & Events**
Tania Balzer Artemide
Senior Manager Marketing & Events

Agostino Bairrao
Congress Manager

Laura Corde Turbers
Marketing & Communication Coordinator

Céline Deschamps
Project Manager Workshops

**Corporate relationships**
Hendie Van Den Berg
Exhibition Project Manager

**Registration & administration**
Sigríð Jacobs-Peeters
Programme Supervisor

Rebecca Harmann
Logistics Administrator

Claire Thomas
Programmes Administrator

**Finance**
Ambrogio Mezzanotte
Senior Finance Manager

Gurkan Uluay
Accounting Coordinator

Dina Andena
Finance & HR Coordinator

**Human Resources**
Nathalie Cropo
Senior HR Manager

**IT**
Michael Berlin
IT Development Manager

Benjamin Correy
IT Support Officer

**ESTRO Cancer Foundation - ECF**
Arina Leci
ECF Project Manager

**Consultants**
Melba Akkers
Education Project Manager

Jill Barnard
Operational Communications

Daniel Bogaerts
Graphic Design

Cécile Hardon-Villard
Strategic Communications

Essi Sarto
Scientific Programme Coordinator

**Gold corporate members**
ACCURAY

BOSTON SCIENTIFIC

CHICAGO RADIOTHERAPY

ELEKTA INSTRUMENT AB

IBA

MM SOFTWARE INC

ORFIT INDUSTRIES

PHILIPS

QIRX

S.I.T. - SCORINIA IORT TECHNOLOGIES S.P.A

SUN NUCLEAR CORPORATION

VARIAN, A SIEMENS HEALTHCARE COMPANY

VIEWRAY

**Corporate members**
Adaptiiv Medical Technologies Inc.

AQUILAB

ArnaDenece PLC

BRAINLAB

Carl Zeiss Meditec AG

C-RAD POSITIONING AB

INTRAOP

KLARITY MEDICAL & EQUIPMENT CO., LTD

LYZE MEDICAL TECHNOLOGIES

MACROMEDICS

MICROPOSS MEDICAL

NANOVA S

PALETTE LIFE SCIENCES

PMB-ALCEN

PTW Freiburg

RAD TECHNOLOGY MEDICAL SYSTEMS

RADFORMATION

RaySearch Laboratories AB (Pub)

SCANDIOS AB

VISION RT Ltd

3. Corporate Members
4. Joint members

**Joint radiation oncology national societies and other oncology societies**

- American Association of Physicists in Medicine (AAPM)
- Association of Medical Physicists of India (AMPI)
- Australasian College of Physical Scientists and Engineers in Medicine (ACPSEm)
- Canadian Association of Radiation Oncology (CARO)
- European Society of Gynaecological Oncology (ESGO)
- International Association for the Study of Lung Cancer (IASLC)
- Iranian Society of Clinical Oncology (ISCO)
- Japanese Society for Radiation Oncology (JASTRO)
- Korean Society of Radiology Technology (KSRT)
- Medical Radiation Technology Society of China (MRTSCH)
- Society of Radiation Therapy Technologists of Mexico (SRTTMex)
- Spanish Society of Radiation Oncology (SEOR)
- Turkish Society of Radiation Oncology (TSRO)

5. RTT Alliance

**European RTT Alliance Members**

- Austria: Society of Radiological Technology Austria
- Belgium: Association Francophone des Techniciens Exerçant en Radiothérapie
- Greece: Hellenic Association of Medical Physicists (HAMP)
- Ireland: Irish Institute of Radiography and Radiation Therapy
- Italy: Italian Association of Radiation Therapists and Medical Physic Technologists
- Macedonia: Association and Chamber of Radiological Technologists of Macedonia
- Malta: Society of Medical Radiographers
- Poland: Polish Society of Electroradiology
- Portugal: Portuguese Association of Radiation Therapists
- Serbia: Serbian Society of Radiotherapy Technicians
- Spain: Spanish Society for Radiotherapy and Oncology
- Switzerland: Swiss Association of Radiographers
- Turkey: Society of Radiation Therapy Technologists

**Global RTT Alliance Members**

- Brazil: Associação de Técnicos e Tecnólogos em Radioterapia de Rio Grande do Sul
- Chile: Sociedad Chilena de Radioterapia Oncológica
- India: Association of Radiation Therapy Technologists of India
- Tanzania: Radiotherapists’ Association of Tanzania
6. Institutional Members

Belgium
AZ Turnhout
CHU Liège
GZA Ziekenhuizen, Sint Augustinus - Iridium Kankercentrum Antwerpen
Institut Jules Bordet
University Hospital Gasthuisberg (UZ Leuven)
Universitair Ziekenhuis Brussel

Czech Republic
University Hospital Hradec Kralove

Denmark
Aalborg University Hospital
Odense University Hospital

Estonia
North Estonian Regional Hospital Cancer Center

France
Institut de Radioprotection et de Sûreté Nucléaire
Centre Oscar Lambret
Centre Léon Bérard
Institut Curie
Institut Gustave Roussy

Germany
Gemeinschaftspraxis fuer Strahlentherapie Siegen-Friedrichshafen
Klinikum Rechts Der Isar, TU Munich
Klinik und poliklinik für Strahlentherapie und Radioonkologie (Munich)

Hungary
University of Debrecen Clinic of Oncology

Italy
AUO Capani - University of Florence
Fondazione IRCCS Istituto Nazionale Tumori
Humanitas Cancer Center
Fondazione ENAD

The Netherlands
Ladon University Medical Center
MAASTRO
NIH - Netherlands Cancer Institute
Red Lion University Medical Center
Radiotherapiegrup Venlo (Deventer)
The Netherlands Institute for Cancer Research UMC Utrecht
VU University Medical Center
Maastricht University

Poland
Greater Poland Cancer Center

Portugal
Joaquim Chaves Clinica e Medicas Ambulatario

Romania
Regional Institute of Oncology Iasi

Russia
OnesStop

Spain
Institut IMOB
Fundacio Institut d’Investigacio Biomedica de Bellvitge (IDIBELL)

Sweden
Karolinska University Hospital
Södersjukhuset AB

Switzerland
Basel, St. Claraspital
Basel, Universitäts Spital Basel (USB)
Bellinzona, Ospedale San Giovanni (DCC)
Bern, Inselspital (Universitats Spital Bern)
Chur, Kantonsspital Graubünden (KSGR)
Fribourg, Hôpital cantonal (HFR)
Genève, Hôpitaux Universitaires (HUG)
Gensérer, Clinique de Gensérer
La Chaux-de-Fonds, Réseau hospitalier neuchâtelois (RHN)
Lausanne, Centre Hospitalier Universitaire Vaudois (CHUV)
Lausanne, Clinique La Source
Lausanne, Hirslanden Clinique de Bosio-Cerf
Loggip, Gruppo Ospedaliero Montecucco
Luzern, Kantonsspital
Paul Scherrer Institut (PSI)
Radio-Onkologie-Zentrum KSA-KSB
Sion, Hopital du Valais
St. Gallen, Kantonsspital (KSSG)
Winterthur, Kantonsspital Winterthur (KSW)
Zürich, Städtspital Triemli
Zürich, Universitäts Spital Zürich (USZ)

UK
Velindre University NHS Trust
Western General Hospital, Edinburgh Cancer Centre

Zambia
Cancer Diseases Hospital
8. Awards

ESTRO Award Lectures
Evangelist Van der Schueren Award
Peter van der Heijden (NL)
Radiation therapy: Art or science?

Jens Overgaard Legacy Award
Sigrid Van der Heiden (DK)
Evidence generating radiation therapy trials and guidelines through collaboration

Donal Hollywood Award
Linda Kervin (NL)
Patterns of failure in the phase II randomized controlled FLAME trial for localized prostate cancer

Klaus Buerk Award
Jan’s Igniter (NL)
The last of the Radiation therapy: The next generation standard?

Honorary Physicist
Constanza Laveissière (UK)
The last of the Honorary Physicists

GEC-ESTRO Iridium 192 Award - In Memoriam of Janusz Skowronek
Piotr Wojcieszek on behalf of Janusz Skowronek (PL)
You’ll never walk alone - The lesson Late Prof Janusz Skowronek taught me

Award Presentations

Lifetime Achievement Awards
Vesko Vuletic (IT)
David Breslin (UK)
Hakan Nyström (SE)
Lars Specht (DK)

Honorary Member Awards
Lisette Haagensen (DK)
Mary Asplund-Holm (AT)
Thomas Barnhill (USA)

ESTRO Academic Award
Jack Elshorshy University of Wisconsin Award
Sharbatchi Edward (USA)
Source of errors in radiation therapy as assessed with the HDR lung, Head & neck and spine phantoms

Company Awards
ESTRO Elekta Brachytherapy Award
Ignacio Vinuesa (ES)
IGBR brachytherapy boost improves metastatic free survival in high and very high risk prostate cancer

GEC-ESTRO Best Junior Presentation - sponsored by Elekta Brachytherapy
Monica Serban (CA)
Effect of dose and fractionation de-escalation in low-risk cervix cancer treated with EBRT and BT

Best Paper Awards

Best Clinical Paper Award
Tine Træna (DK)
CD2 positive cells indicate increased post mastectomy randomized controlled FLAME trial for localized prostate cancer

Best Physics Paper Award
Yvonne Briel (NL)
Salvatory gland dose response modelling using PAMIR EETRI

Best RTT Paper Award
Piera Kinner (NL)
Predicted reduction in ANZCT by model based selected proton therapy for esophageal cancer patients

Company Awards
GEC-ESTRO Best Junior Presentation - sponsored by Elekta Brachytherapy
Monica Serban (CA)
Brachytherapy treatment verification using a moving phantom

Best Interdisciplinary Paper Award
Yolande Leveaux (BE)
Carcinogenesis: Clinical evidence: Developing real-life evidence on SBRT in Belgium

Best Radiobiology Paper Award
Brita Singer’s Sørensen (DK)
Radiobiological effects of 3D-RAD21 on tumor control and skin toxicity in a mouse leg model

Best Brachytherapy Paper Award
Monica Serban (CA)
Effect of dose and fractionation de-escalation in low-risk cervix cancer treated with EBRT and BT

Youth Researcher Awards

cTRO Award – sponsored by Elsevier
Sara van Marle (IT)
Sensitisation CT Skeletal Muscle Index as a Biomarker for CTRT compliance and survival in rectal cancer

phBRO Award – sponsored by Elsevier
Gisela Göttingen (FR)
Phase III randomized controlled trial on prostate cancer: Improved oncological outcomes in patients with painful rectal metastases treated with SBRT

ipsRO Award – sponsored by Elsevier
Sophie Alexander (UK)
Systematic multi-disciplinary sequence evaluation for integration into the MRI-linac workflow

Young Researcher Award

ctRO Award – sponsored by Elsevier
Sara van Marle (IT)
Sensitisation CT Skeletal Muscle Index as a Biomarker for CTRT compliance and survival in rectal cancer

ipsRO Award – sponsored by Elsevier
Sophie Alexander (UK)
Systematic multi-disciplinary sequence evaluation for integration into the MRI-linac workflow

Young ESTRO Award
Jenny Bertholet
Barthomay Tamás

Radiology corner
Radiology Committee
ROST
Mary Coffey
Course reports
Education team
Young ESTRO corner
Jenny Bertholet
Barthomay Tamás